ARO-C3 / Arrowhead - LARVOL DELTA

ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, and Complement Activity in IgAN Patients (ERA 2025) - No abstract available

Clinical • Late-breaking abstract • Glomerulonephritis • IgA Nephropathy • Renal Disease

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease (clinicaltrials.gov) - P1/2 | N=62 | Active, not recruiting | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1 ➔ P1/2

Phase classification • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy (Businesswire) - P1/2a | N=62 | NCT05083364 | Sponsor: Arrowhead Pharmaceuticals | "Patients with IgA nephropathy (IgAN) (n=14) received subcutaneous doses of ARO-C3 (400 mg) on Days 1, 29, and 113 and were followed through Day 169....Effects on proteinuria: Mean reduction in spot UPCR of 41% and maximum individual reduction of 89% from baseline by week 24. Safety and Tolerability: ARO-C3 was generally well-tolerated in patients with IgAN; No serious or severe treatment emergent adverse events (TEAE) and no TEAEs that led to study or study drug discontinuation; The only TEAEs reported in more than 1 subject were headache, cough, and nasopharyngitis....'We look forward to sharing more data from the Phase 1/2 clinical study of ARO-C3 at an upcoming medical meeting in 2025'."

P1/2 data • IgA Nephropathy

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease (clinicaltrials.gov) - P1 | N=62 | Active, not recruiting | Sponsor: Arrowhead Pharmaceuticals | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2024 ➔ May 2025

Enrollment closed • Trial primary completion date • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Trial completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Arrowhead Pharmaceuticals

Trial completion date • Trial primary completion date • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1/2 ➔ P1

Phase classification • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. (PubMed, Immunol Rev) - "This review explains key concepts of RNA and DNA targeting and discusses assets in clinical development for the treatment of diseases driven by the alternative pathway, including the RNA-targeting therapeutics ALN-CC5, ARO-C3, and IONIS-FB-LRX, and the gene therapies GT005 and HMR59. These therapies are but the spearhead of potential drug candidates that might revolutionize the field in coming years."

Journal • Review • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Gene Therapies • Hematological Disorders • Inflammation • Macular Degeneration • Ophthalmology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Retinal Disorders

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | N=62 ➔ 84

Enrollment change • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • IgA Nephropathy • Nephrology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Renal Disease

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease (clinicaltrials.gov) - P1/2 | N=62 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • IgA Nephropathy • Nephrology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Renal Disease